Clinical Trial Update: Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating HCD122 in adults with Non-Hodgkin's or Hodgkin's lymphoma following at least two prior therapies has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• HCD122

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED